Biosimilars also known as similar biological products, follow-up biologics, subsequent entry biological, second entry biological, biogenerics, multisource products, and off-patent biotech products as synonyms. Biosimilars are a type of biological product that is licensed (approved) by the FDA because they are highly similar to an already FDA-approved biological product, known as the biological reference product (reference product) and have been shown to have no clinically meaningful differences from the reference product. Biosimilars are a new class of drugs intended to offer comparable safety and efficacy to the reference, off-patent biological. Minor differences in clinically inactive components are allowed, however there must be no clinically meaningful differences between the biosimilar and the reference product in terms of the safety, purity, and potency of the product. A biosimilar can be approved only for those indications and condition(s) of use previously approved for the reference product. The problems/limitations with biosimilar are that, the two biosimilar have a different origin, the two biosimilars may have same therapeutic effect, may have different side-effects and hence require thorough testing.
The global biosimilar drugs market segmentation is based on drug type (erythropoietin, human growth hormones, insulin, monoclonal antibodies, peptides, others), and application (chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, oncology, others).
The global biosimilar drugs market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global biosimilar drugs market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World. The global biosimilar drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major players operating in the global biosimilar drugs market and profiled in this report include Allergan plc, BIOCAD, Biocon, BioXpress Therapeutics SA, Boehringer Ingelheim GmbH, Celltrion, Inc., Coherus BioSciences, Inc., Dr. Reddy’s Laboratories Ltd., Genor BioPharma Co. Ltd, Intas Pharmaceuticals Limited, Novartis AG, Pfizer, Inc., and Reliance Life Sciences.